This kind of statement in a PR for almost any othe
Post# of 36537
Mr. Moscato will also discuss the signed non-binding memorandum of understanding with China for the Ii-Key-SARS-CoV-2 vaccine program in China, which is expected to become effective upon signing the final contractual agreements. Under the terms of the MOU, Generex will receive an upfront $5 million payment, the Chinese partners will fund 100% of the development costs, and Generex will be paid a minimum of $400 million when the vaccine is approved for commercial sale in China.